GlassScriptPhysician profile
Renae M Slobodny
NPI 1528586641
$4,448.87
in general payments reported to CMS, 2019-2025
26 companies · $1,656 in 2025
The $1,656 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $235 · 2023: $890 · 2024: $1,518 · 2025: $1,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,063.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $891.16 | 2023-2025 | |
| Abbvie INC. | $496.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.97 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $327.86 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $257.01 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $223.08 | 2025 | Nemluvio |
| Organon LLC | $212.60 | 2024-2025 | Vtama |
| Incyte Corporation | $197.42 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $185.68 | 2021-2023 | Jublia |
| Ucb, INC. | $181.37 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $161.78 | 2024-2025 | |
| Almirall LLC | $139.79 | 2022-2024 | Seysara |
| Lilly USA, LLC | $125.94 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Blueprint Medicines Corporation | $107.20 | 2024-2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $105.80 | 2024 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $95.08 | 2024-2025 | |
| Amgen INC. | $82.99 | 2024-2025 | Otezla, Otezla |
| Organogenesis INC. | $70.73 | 2025 | Puraply Wound Matrix |
| Leo Pharma INC. | $47.16 | 2023-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $25.22 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $24.18 | 2025 | |
| Lnhc, INC | $21.65 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $19.48 | 2025 | |
| Mimedx Group, INC. | $16.72 | 2024 | |
| Biowound Solutions, INC. | $13.18 | 2025 | Bio-Connekt |
| Mayne Pharma Commercial LLC | $7.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renae Slobodny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.